Aug 17, 2023 · AREXVY is now widely available in major retail pharmacies and anticipated to be covered by most Medicare and commercial insurance plans.

Aug 30, 2024 · Three RSV vaccines are currently available for adults ages 60 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. Eligible older adults may receive any of the …

Find more information about AREXVY, a respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. Learn about side effects, coverage, and where to get AREXVY.

Aug 17, 2023 · And now—well in advance of the fall and winter RSV season—Arexvy is available in major U.S. retail pharmacies, GSK said Thursday. Under the Inflation Reduction Act, …

Aug 17, 2023 · Arexvy (respiratory syncytial virus vaccine, adjuvanted) is now available for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …

May 3, 2023 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases …

Aug 18, 2023 · AREXVY was approved by the US Food and Drug Administration (FDA) on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory …

Aug 17, 2023 · GSK plc (LSE/NYSE: GSK) today announced that AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the US at all major retail pharmacies.

Dec 10, 2023 · Health Canada approved Arexvy in August for adults aged 60 and over. There is no approved vaccine for children or younger adults. In a clinical trial published earlier this year, …

Aug 1, 2023 · The FDA approved GSK’s Arexvy on May 3, 2023, making it the first vaccine to prevent lower respiratory tract disease caused by RSV in adults aged 60 and older. The …